Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term antagonists & inhibitors. Found 120 abstracts

no pagination
Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr;35(10):1112-8.   PMCID: PMC5559878
Sznol M, Postow MA, Davies MJ, Pavlick AC, Plimack ER, Shaheen M, Veloski C, Robert C. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev. 2017 Jul;58:70-6.
Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Muschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood. 2016 Apr 28;127(17):2131-43.   PMCID: PMC4850868
Haldane A, Flynn WF, He P, Vijayan RS, Levy RM. Structural propensities of kinase family proteins from a Potts model of residue co-variation. Protein science : a publication of the Protein Society. 2016 Aug;25(8):1378-84.   PMCID: PMC4972195
Huang F, Goyal N, Sullivan K, Hanamshet K, Patel M, Mazina OM, Wang CX, An WF, Spoonamore J, Metkar S, Emmitte KA, Cocklin S, Skorski T, Mazin AV. Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors. Nucleic acids research. 2016 May 19;44(9):4189-99.   PMCID: PMC4872086
Ji W, Arnst C, Tipton AR, Bekier ME, Taylor WR, Yen TJ, Liu ST. OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases. PLoS One. 2016 Jan;11(4):e0153518.   PMCID: PMC4833387
Prudnikova TY, Villamar-Cruz O, Rawat SJ, Cai KQ, Chernoff J. Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells. Oncogene. 2016 Apr 28;35(17):2178-85.   PMCID: PMC5125076
Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res. 2016 Jan;22(1):34-43.
Zibelman M, Plimack ER. Checkpoint Inhibitors and Urothelial Carcinoma: The Translational Paradigm. Oncology (Williston Park). 2016 Feb;30(2):160-2, 176.
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. The New England journal of medicine. 2015 Jan 22;372(4):311-9.   PMCID: 4348009
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. The New England journal of medicine. 2015 Oct 22;373(17):1627-39.
Chakraborty AK, Mehra R, Digiovanna MP. Co-targeting ER and HER family receptors induces apoptosis in HER2-normal or overexpressing breast cancer models. Anticancer research. 2015 Mar;35(3):1243-50.
Di Marcantonio D, Galli D, Carubbi C, Gobbi G, Queirolo V, Martini S, Merighi S, Vaccarezza M, Maffulli N, Sykes SM, Vitale M, Mirandola P. PKCepsilon as a novel promoter of skeletal muscle differentiation and regeneration. Exp Cell Res. 2015 Nov 15;339(1):10-9.
Eidem TM, Lounsbury N, Emery JF, Bulger J, Smith A, Abou-Gharbia M, Childers W, Dunman PM. Small-molecule inhibitors of Staphylococcus aureus RnpA-mediated RNA turnover and tRNA processing. Antimicrob Agents Chemother. 2015 Apr;59(4):2016-28.   PMCID: PMC4356807
Gianti E, Carnevale V, DeGrado WF, Klein ML, Fiorin G. Hydrogen-bonded water molecules in the M2 channel of the influenza A virus guide the binding preferences of ammonium-based inhibitors. J Phys Chem B. 2015 Jan 22;119(3):1173-83.   PMCID: PMC4386636
Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, Adams S. CTLA-4 blockade synergizes therapeutically with PARP-inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol Res. 2015 Jul 02;3(11):1257-68.   PMCID: 4984269
Hochster HS, Uboha N, Messersmith W, Gold PJ, O Neil BH, Cohen D, Denlinger C, Cohen S, Leichman CG, Leichman L, Lenz HJ. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol. 2015 Jan;75(1):17-23.
Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Lambert AM, Waxman IM, Hammers HJ. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol. 2015 May;33(13):1430-7.   PMCID: PMC4806782
Pawlikowski JS, Brock C, Chen SC, Al-Olabi L, Nixon C, McGregor F, Paine S, Chanudet E, Lambie W, Holmes WM, Mullin JM, Richmond A, Wu H, Blyth K, King A, Kinsler VA, Adams PD. Acute Inhibition of MEK Suppresses Congenital Melanocytic Nevus Syndrome in a Murine Model Driven by Activated NRAS and Wnt Signaling. The Journal of investigative dermatology. 2015 Aug;135(8):2093-101.   PMCID: 4539947
Prudnikova TY, Rawat SJ, Chernoff J. Molecular Pathways: Targeting the Kinase Effectors of RHO-Family GTPases. Clinical Cancer Research. 2015 Jan;21(1):24-9.   PMCID: 4286478
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term antagonists & inhibitors

antagonists & inhibitors metabolism drug therapy Female therapeutic use Antineoplastic Agents genetics pathology drug effects adverse effects Middle Aged Signal Transduction pharmacology Male immunology Aged chemistry Monoclonal Antibodies administration & dosage Mice Adult physiology Protein Kinase Inhibitors Drug Dose-Response Relationship Cell Proliferation therapy Molecular Targeted Therapy Neoplasm Drug Resistance Immunotherapy Treatment Outcome Monoclonal Antibodies-Humanized CD274 Antigens Ovarian Neoplasms Tumor Cell Line mortality Mutation Programmed Cell Death 1 Receptor Drug Administration Schedule analysis Cell Cycle Checkpoints Neoplasms Apoptosis Inbred C57BL Mice Retreatment biosynthesis Immunoconjugates CTLA-4 Antigen Disease-Free Survival High-Throughput Screening Assays Cell Cycle MAP Kinase Kinase Kinases diagnosis Survival Analysis chemically induced Inhibitory Concentration 50 enzymology Protein Binding analogs & derivatives Neoplasm Proteins Thermodynamics Oncogene Proteins v-abl Cell Survival 80 and over Aged apoptosis Xenograft Model Antitumor Assays derivatives Kaplan-Meier Estimate Stem Cell Transplantation Anti-Bacterial Agents BRCA1 Protein kinase Diarrhea Programmed Cell Death 1 Ligand 2 Protein SCID Mice Immune-related adverse events Proto-Oncogene Proteins Urologic Neoplasms Molecular Dynamics Simulation Lymphoma HeLa Cells Lung Neoplasms Trastuzumab Microbial Sensitivity Tests Janus Kinases Mitogen-Activated Protein Kinase 14 Muscle Development Neoplastic Stem Cells Estrogen Antagonists trastuzumab (Herceptin) Proto-Oncogene Proteins c-abl Experimental Leukemia Melanoma Thiourea Maximum Tolerated Dose Immunoenzyme Techniques Potts model Fatigue fulvestrant (Faslodex) Skin Neoplasms Real-Time Polymerase Chain Reaction Western Blotting Hypotension Reed-Sternberg Cells Camptothecin Disease Progression conformational preference Hydrogen Bonding Small Interfering RNA rho GTP-Binding Proteins Cisplatin Skeletal Muscle Carcinogenesis Molecular Models Breast Neoplasms Amino Acid Motifs M Phase Cell Cycle Checkpoints Local Neoplasm Recurrence Fallopian Tube Neoplasms Nivolumab Cell Line Small Molecule Libraries Secondary Protein Structure Hmga1 Carcinoma Non-Small-Cell Lung Carcinoma Intravenous Administration use Finland Kinetics Oxidative Stress Canada Proportional Hazards Models Taxoids estrogen receptor (ER) Ubiquitin-Protein Ligases T-Lymphocyte Subsets Animal Disease Models Water Pyridazines deficiency PKCepsilon Phosphotransferases Ribonuclease P Urothelium ras Proteins Protein Databases Reverse Transcriptase Polymerase Chain Reaction Imidazoles Ammonium Compounds Monomeric GTP-Binding Proteins
Last updated on Wednesday, September 06, 2017